Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Infinium PharmachemNSE:INFINIUM -1.12%90 EV-to-EBITDA is 17.87 as of Sep. 21, 2026, which is 3% above its 10-year median of 17.43. GuruFocus rates NSE:INFINIUM with a GF Score™ of 90/100 and a GF Value™ of ₹312.42 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,409 Chemicals companies, Infinium Pharmachem ranks worse than 66.78% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Infinium Pharmachem's enterprise value is ₹4,237 Mil.
Infinium Pharmachem's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹237 Mil. Therefore, Infinium Pharmachem's EV-to-EBITDA for today is 17.87.
The historical rank and industry rank for Infinium Pharmachem's EV-to-EBITDA or its related term are showing as below:
NSE:INFINIUM'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.19 Med: 17.43 Max: 26.96
Current: 17.87
During the past 7 years, the highest EV-to-EBITDA of Infinium Pharmachem was 26.96. The lowest was 8.19. And the median was 17.43.
NSE:INFINIUM's EV-to-EBITDA is ranked worse than 66.78% of 1409
companies
in the Chemicals industry
Industry Median: 11.36
vs NSE:INFINIUM: 17.87
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Infinium Pharmachem's PE Ratio (TTM) for today is calculated as:
Infinium Pharmachem's share price for today is ₹265.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Infinium Pharmachem's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹7.797.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Infinium Pharmachem's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Chemicals subindustry, Infinium Pharmachem's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Infinium Pharmachem EV-to-EBITDA vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Infinium Pharmachem's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Infinium Pharmachem's EV-to-EBITDA falls into.
Infinium Pharmachem's current Enterprise Value is ₹4,237 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Infinium Pharmachem's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹237 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Infinium Pharmachem (NSE:INFINIUM) has a EV-to-EBITDA of 17.87 as of Sep. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Infinium Pharmachem. This is near median its historical median of 17.43. Over the past decade, Infinium Pharmachem's EV-to-EBITDA has ranged from 8.19 to 26.96. According to the industry distribution chart, Infinium Pharmachem ranks #941 out of 1409 companies in the Chemicals industry, placing it in the top 66.8%.
Is Infinium Pharmachem's EV-to-EBITDA too high?
Infinium Pharmachem's current EV-to-EBITDA of 17.87 is near median its 10-year median of 17.43. Over the past 10 years, this metric has ranged from a low of 8.19 to a high of 26.96. The Chemicals industry median EV-to-EBITDA is 11.36. Infinium Pharmachem's value of 17.87 is 57.3% above this industry median. Based on the distribution chart, Infinium Pharmachem ranks #941 out of 1409 companies in the Chemicals industry, which is below the industry midpoint. Overall, Infinium Pharmachem has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Infinium Pharmachem's EV-to-EBITDA compare to DOW?
According to the Chemicals industry distribution chart, Infinium Pharmachem ranks #941 out of 1409 companies for EV-to-EBITDA. This places Infinium Pharmachem in the lower half of its industry. The industry median EV-to-EBITDA is 11.36. Infinium Pharmachem's value of 17.87 is 57.3% above this benchmark. Historically, Infinium Pharmachem's own EV-to-EBITDA has ranged from 8.19 to 26.96 over the past decade. While the company's 10-year median is 17.43 vs. the industry median of 11.36, Infinium Pharmachem has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Chemicals company?
The median EV-to-EBITDA among Chemicals companies is 11.36, based on 1,409 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Infinium Pharmachem's current EV-to-EBITDA of 17.87 is 57.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Infinium Pharmachem. For the Chemicals industry, the median EV-to-EBITDA is 11.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Infinium Pharmachem's current EV-to-EBITDA is 17.87, which is near median its own 10-year median of 17.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Infinium Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Infinium Pharmachem (NSE:INFINIUM) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹312.42, compared to a current price of ₹265.00 — trading 15.2% below its estimated fair value. The current EV-to-EBITDA is 17.87, which is near median its 10-year median of 17.43 and 57.3% above the Chemicals industry median of 11.36. Infinium Pharmachem's overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Infinium Pharmachem (NSE:INFINIUM), the current EV-to-EBITDA is 17.87 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Infinium Pharmachem (NSE:INFINIUM) Overvalued in 2026?
Based on GuruFocus' analysis, Infinium Pharmachem stock appears to be undervalued.
The current stock price of ₹265.00 is trading 15.2% below its estimated GF Value™ of ₹312.42.
GuruFocus considers Infinium Pharmachem to be Modestly Undervalued.
Key valuation signals for NSE:INFINIUM:
EV-to-EBITDA: 17.87 (near median its 10-year median of 17.43)
GF Value™: ₹312.42 vs. price of ₹265.00 (15.2% below fair value)
Industry Position: 57.3% above the Chemicals median (#941 of 1409)
No single metric tells the full story. See the NSE:INFINIUM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Infinium Pharmachem Ltd is engaged in the business of manufacturing and supplying Iodine, Iodine Derivatives and Active Pharmaceutical Ingredients (APIs). It provides fully integrated customized services from R & D to Commercial scale manufacturing and packaging for its products to the Pharmaceutical, Agrochemical, Nutraceutical, Speciality Chemicals and various other chemicals Industries.
90GF Score
Get the complete analysis for NSE:INFINIUM
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INFINIUM has been successfully added to your 
